Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Search by treatment name :

Display new or updated analyses

Display all results

Your research: comparisons updated with new studies

Access the forest plots for the 15 treatment comparisons .

    Anti-virals (3 comparisons)

    Other antimicrobials (antibiotics, antimalarials, antiparasitics) (1 comparisons)

    Kinase inhibitor (1 comparisons)

    Corticosteroids (1 comparisons)

    Monoclonal antibodies (4 comparisons)

    Immunosupressant (1 comparisons)

    Convalescent plasma (1 comparisons)

    Antithrombotic (antiplatelet, anticoagulant, thrombolytic drug) (2 comparisons)

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
New
NCT04425915
COPLA-II trial
Bajpai M, BMJ Open, 2022
Full text
Commentary
Commentary
No specific funding

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in India. N=400
Some concerns
Details

Full description

New
NCT04438980 ; EudraCT 2020-001827-15
CORTIVID
Les I, Front Med , 2022
Full text
Commentary
Commentary
Public/non profit

Intravenous Methylprednisolone pulse

Placebo

RCT Patients with confirmed COVID-19 (moderate) admitted to 2 centers in Spain. N=72
Low
Details

Full description

New
NCT04405310
Fernandez-Sanchez V, Research Square, 2022
Full text
Commentary
Commentary
Public/non profit

Convalescent plasma

Placebo

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to two centers in Mexico N=43
Some concerns
Details

Full description

New
NCT04505774
ACTIV-4a
Berger JS, JAMA, 2022
Full text
Commentary
Commentary
Public/non profit

Therapeutic anticoagulant + P2Y12 Inhibitor

Therapeutic anticoagulant

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 60 centers in Brazil, Italy, Spain and USA. N=562
Some concerns
Details

Full description

New
CTRI/2020/07/026835
Nair PR, Respir Care, 2021
Full text
Commentary
Public/non profit

Noninvasive ventilation

High flow nasal cannula

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in India. N=109
Some concerns
Details

Full description

NCT04356495, EudraCT 2020-001435-27
COVERAGE
Duvignaud A, Clin Microbiol Infect, 2022
Full text
Commentary
Public/non profit

Ciclesonide

Standard care

RCT Outpatients with confirmed COVID-19 (symptomatic) treated by 14 centers in France N=217
Some concerns
Details

Full description

NCT04351243
BREATHE
Criner GJ , Am J Respir Crit Care Med, 2022
Full text
Commentary
Private

Gimsilumab

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 21 centers in the USA. N=227
Some concerns
Details

Full description

NCT04673162 ; EudraCT 2020-004323-16
Salvarani C, Eur Respir J, 2022
Full text
Commentary
No specific funding

Methylprednisolone

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 19 centers in Italy. N=304
Low
Details

Full description

IRCT20200506047323N3
Hassaniazad M, J Med Virol, 2022
Full text
Commentary
Public/non profit

Favipiravir

Lopinavir + Ritonavir

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=66
Some concerns
Details

Full description

IRCT20151227025726N14
Tabarsi P, Iran J Pharm Res, 2021
Full text
Commentary
Commentary
Public/non profit

Favipiravir

Lopinavir + Ritonavir

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=62
Some concerns
Details

Full description